CATALYST DOSSIER · UPDATED 2026-11-05
$BYSI
biotech · convergence 5 · conviction WATCH
Price & Live Quote Loading live quote & chart…
Practice trade tools Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.
Paper trade unavailable: missing risk-bounded frame
Reference only. Not financial advice. No brokerage order is placed.
Why $BYSI?
Quantitative
Net Income (CY2026Q2) : $-849.0K (+53.0% YoY)
Catalysts
Multi-spoke convergence : 8 convergent signals fired: earnings, gap, xbrl_ni, sec_fda, audit_extras
Risks
Position-sizing discipline : Conviction WATCH (5 score) — size accordingly; no specific catalyst-fade risk flagged
Bear case
Earnings binary : Print-day moves can swing ±15% — gap risk both directions
Sympathy basket (cerebro)
APP via tech r=+0.81 sympathetic (score 19)
STEM via tech r=+0.81 sympathetic (score 19)
LBTYA via comms r=+0.62 sympathetic (score 16)
CHTR via comms r=+0.62 sympathetic (score 7)
Signals Firing
earnings gap xbrl_ni sec_fda audit_extras auto_macro_adp_payrolls auto_macro_durable_goods auto_macro_fx_rates
Pick Track Record Date List Next-day max run Next-day close Hit +2%? 2026-10-13 sec_clean_gappers +4.6% -3.3% ✓ hit 2026-10-13 sec_top_gappers +4.6% -3.3% ✓ hit 2026-10-13 sec_top_moat_emerging +4.6% -3.3% ✓ hit 2026-10-06 sec_top_gappers +0.0% -6.8% — 2026-10-06 sec_top_moat_emerging +0.0% -6.8% — 2026-10-02 sec_top_gappers +5.8% -0.1% ✓ hit 2026-10-02 sec_top_moat_emerging +5.8% -0.1% ✓ hit 2026-09-18 sec_top_gappers +2.7% -1.3% ✓ hit 2026-09-18 sec_top_moat_emerging +2.7% -1.3% ✓ hit 2026-09-14 sec_top_gappers +5.3% -1.2% ✓ hit 2026-09-14 sec_top_moat_emerging +5.3% -1.2% ✓ hit 2026-09-08 sec_top_gappers +1.6% +1.5% —
Lifetime: 9/13 wins · hit-rate 69.2% on +2% intraday
Sympathy Basket APP via tech · score 19 STEM via tech · score 19 LBTYA via comms · score 16 CHTR via comms · score 7
Earnings Catalyst No recent earnings event.
Generate full earnings report
Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks
and its losses — see the
trust report and
methodology .
Not financial advice. Confirm independently before trading.